Fundz

Envisagenics, Inc. reported raising in an initial SEC Form D filing, from an offering of $2 Million

PRIVATEMar 03, 2017$0 of $2M raised

Round Type

Venture

New YorkBiotechnologyData And AnalyticsHealth CareScience And EngineeringArtificial Intelligence

Quick answer

Envisagenics raised an undisclosed amount in a funding round, dated March 3, 2017. Envisagenics is based in New York, New York, United States.

How much did Envisagenics raise?
Envisagenics raised an undisclosed amount in a funding round on March 3, 2017.
What does Envisagenics do?
Envisagenics is an AI-driven biotechnology company harnessing the therapeutic potential of RNA splicing.
Where is Envisagenics based and how big is it?
Envisagenics is based in New York, New York, United States.

Source: Fundz verified event record.

Who else raised in Data And Analytics and Science And Engineering around the same time

Companies in the same sectors as Envisagenics that raised within 45 days of this round, from Fundz verified event records.

  • Cardurion Pharmaceuticals raised $16M on April 4, 2017.
  • Viracta Therapeutics raised $9.9M on April 5, 2017.
  • AliveCor, Inc. raised $30M on March 30, 2017.
  • QView Medical raised $2M (Seed) on March 13, 2017.
  • Gestalt Diagnostics raised $2.6M on March 10, 2017.
  • MIXMODE raised $654K (Seed) on February 23, 2017.

Who to call at Envisagenics, and when

A new round usually means Envisagenics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Envisagenics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Envisagenics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Envisagenics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Envisagenics

Location

New York, New York, United States

About

Envisagenics is an AI-driven biotechnology company harnessing the therapeutic potential of RNA splicing. Over 95% of human genes undergo alternative splicing, a process generating multiple RNA isoforms from a single gene. Alternative splicing holds the key to understanding and targeting over 370 diseases, including cancer and neurodegenerative disorders. SpliceCore boasts an impressive 400-fold increase in transcriptomic search space compared to conventional tools for target identification. Leveraging our extensive map of over 14 million RNA splicing events, SpliceCore enables the discovery of disease-specific targets, paving the way for the rational design and development of RNA therapeutics and immunotherapies.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Envisagenics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Envisagenics's next move

See what Strategic adds

Envisagenics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.